Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time.
A Chronic Disease Finally Meets a Long-Term Plan
Eosinophilic…